Surgery Clinical Trial
Official title:
Surgical Treatment of Peri-implantitis Using a Bone Substitute With or Without a Resorbable Collagen Membrane. A Randomized Clinical Trial
Verified date | April 2024 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of the present randomized clinical trial will be to compare two surgical methods of treating peri-implantitis. This study will determine if surgical debridement of peri-implantitis bone defects, including air decontamination of implant surfaces, in combination with the placement of a bone graft, differs in treatment outcomes compared to placing the same bone graft material with a resorbable collagen membrane placed over the bone graft.
Status | Enrolling by invitation |
Enrollment | 52 |
Est. completion date | December 2026 |
Est. primary completion date | January 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: To be enrolled, the participant must meet the following inclusion criteria: 1. age 18 years or older 2. be patients of record at the University of Pittsburgh Periodontics Department 3. Systemically healthy patients 4. Full-mouth plaque score and full-mouth bleeding score = 30% (measured at six sites per tooth) 5. Study individuals will be included if they met the following criteria: (a) one or more peri-implant sites with PPD =6 mm combined with BOP/suppuration, and (b) peri-implant marginal bone loss, defined as a crater like defect =3 mm as assessed from intra- oral radiographs, (c) Infrabony circumferential defect of more than 270° determined by CBCT, (d) crown not possible to retrieve before surgery Exclusion Criteria:study individuals will be excluded if any of the folllowing apply: 1. Unlikely to be able to comply with study procedures and unable to return to SDM for multiple appointments over the course of about a year. 2. Uncontrolled pathologic processes in the oral cavity (cancer and active periodontal disease) 3. History of allergic reactions to dental local anesthetics 4. History of head and neck chemotherapy or radiation within 5 years prior to surgery 5. Systemic or local disease or condition that could compromise post-operative healing and/or osseointegration, such as HIV infection, Paget's disease, osteoporosis, etc. 6. Reported diagnosis of diabetes mellitus 7. Patients taking corticosteroids, IV bisphosphonates, or any immunosuppressant medication that could influence post-operative healing and/or osseointegration 8. Smokes more than 10 cigarettes/day (self-reported) 9. History or current medications with known side effects of gingival growth (including any of the following: phenytoin, phenobarbital, lamotrigine, vigabatrin, ethosuximide, topiramate, primidone, nifedipine, diltazem, amlodipine, felodipine, verapamil, cyclosporine). 10. Present alcohol and/or drug abuser (self-reported) 11. Pregnant, unsure pregnancy status, or lactating females (self-reported), or planning to become pregnant within 1 year of study enrollment |
Country | Name | City | State |
---|---|---|---|
United States | University of Pittsburgh School of Dental Medicine | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Andrea Ravida | SigmaGraft Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Successful Treatment of Peri-Implantitis | Composite definition of successful treatment outcome: A composite therapeutic endpoint composed of no evidence of BOP or evidence of BOP grade 1 and with no suppuration at any of four assessed sites per implant PPD =5 mm, and with =1.0 mm defect fill will be used to define a successful treatment outcome. Thickness of soft tissues will be measured with a 1.0-mm marked periodontal probe (UNC, Hu-Friedy, Chicago, IL, USA) on the top of bone crest in the center of the implant. This will ensure direct visibility of mucosal thickness during measurement.
Definition of unsuccessful treatment will mean that the implant does not meet successful treatment outcome criteria or if an implant failure occurs. Implant failure will be defined as implant mobility (assessed from force applied with two hand instrument), pain, or neuropathy. These criteria will be assessed at 12 months post surgery. |
12 months | |
Primary | Clinical Peri-Implant Bone Defect Fill | Peri-implant bone defect depth will be measured clinically during initial surgical procedure and at uncovery to determine clinical bone defect fill (DF). The bone defect will be measured using a prefabricated acrylic stent stabilized on adjacent teeth. The depth will be measured from the marked area of the stent to the deepest point of the defect using a standard periodontal probe and recorded in mm. This will be termed the clinical vertical defect fill (DF), and assessed at each implant site (buccal, lingual/palatal, mesial, distal) as follows: DF = (Measurement at the surgical treatment) - (Measurement at re-entry procedure). | 4 months | |
Primary | Clinical Peri-Implant Bone Defect Resolution | Peri-implant bone defect depth will be measured clinically during initial surgical procedure and at uncovery to determine bone defect resolution. The bone defect will be measured using a prefabricated acrylic stent stabilized on adjacent teeth. The depth will be measured from the marked area of the stent to the deepest point of the defect using a standard periodontal probe and recorded in mm. The defect resolution (DR) will be measured as the percentage of the defect that was filled with bone at the follow up compared to the original defect depth. | 4 months | |
Primary | Peri-Implant Probing Depth | Clinical measurements will be taken at 8 months following the surgical procedure and compared to baseline measurements. Probing depths will be recorded on 6 sites around the implant (mesial facial, distal facial, facial, mesial lingual, distal lingual and lingual). All clinical measurements will be made in millimeters and measured using a standard periodontal probe and by one examiner. | 8 months | |
Primary | Peri-Implant Probing Depth | Clinical measurements will be taken at 12 months following the surgical procedure and compared to baseline measurements. Probing depths will be recorded on 6 sites around the implant (mesial facial, distal facial, facial, mesial lingual, distal lingual and lingual). All clinical measurements will be made in millimeters and measured using a standard periodontal probe and by one examiner. | 12 months | |
Primary | Peri-Implant Bleeding on Probing | Clinical measurements will be taken at 8 months following the surgical procedure and compared to baseline measurements. Following probing measurements, bleeding on probing will be recorded at 6 sites around the implant (mesial facial, distal facial, facial, mesial lingual, distal lingual and lingual). Bleeding will be recorded as present if bleeding occurs within 30 seconds of probing a site and will be recorded as absent if no bleeding occurs. | 8 months | |
Primary | Peri-Implant Bleeding on Probing | Clinical measurements will be taken at 12 months following the surgical procedure and compared to baseline measurements. Following probing measurements, bleeding on probing will be recorded at 6 sites around the implant (mesial facial, distal facial, facial, mesial lingual, distal lingual and lingual). Bleeding will be recorded as present if bleeding occurs within 30 seconds of probing a site and will be recorded as absent if no bleeding occurs. | 12 months | |
Primary | Radiographic Marginal Bone Loss (MBL) | Marginal bone loss (MBL) will be calculated based on standardized radiographs using registered bite-block with a film holder and expressed as the distance from the implant shoulder to the most coronal bone-to-implant contact (BIC) on the mesial and distal side of the implant. The mean values will be calculated for each implant. Peri-implant marginal bone levels will be measured using the ImageJ software. The software will be calibrated for every single image using the known implant length or the length of the implant collar. Measurements of the mesial and distal bone crest level adjacent to each implant will be rounded to the nearest 0.1 mm. Implants with bone up to the coronal margin of the implant collar will be given a value of zero. Mesial and distal measurements of each implant are averaged, and a mean calculated at patient level. | 8 months | |
Primary | Radiographic Marginal Bone Loss (MBL) | MBL will be calculated based on standardized radiographs using registered bite-block with a film holder and expressed as the distance from the implant shoulder to the most coronal bone-to-implant contact (BIC) on the mesial and distal side of the implant. The mean values will be calculated for each implant. Peri-implant marginal bone levels will be measured using the ImageJ software. The software will be calibrated for every single image using the known implant length or the length of the implant collar. Measurements of the mesial and distal bone crest level adjacent to each implant will be rounded to the nearest 0.1 mm. Implants with bone up to the coronal margin of the implant collar will be given a value of zero. Mesial and distal measurements of each implant are averaged, and a mean calculated at patient level. | 12 months | |
Secondary | Patient Reported Pain Outcomes | Patients will be provided with numerical pain assessment forms following each surgical intervention and these forms will be collected at the post operative visits. Patients will be instructed to record post operative pain using a numerical Pain Scale with 0 being no pain and 10 being the worst pain. Patients will begin recording pain scales starting the day of surgery and continue daily for 7 days. Patient will return the completed form at the 4 week post operative visit following the first surgical procedure. This data will be used to assess if there are any differences in patient reported pain outcomes between both groups. | 4 weeks | |
Secondary | Patient Reported Pain Outcomes | Patients will be provided with numerical pain assessment forms following each surgical intervention and these forms will be collected at the post operative visits. Patients will be instructed to record post operative pain using a numerical Pain Scale with 0 being no pain and 10 being the worst pain. Patients will begin recording pain scales starting the day of surgery and continue daily for 7 days. Patient will return the completed form at the 2 week post operative visit following the uncovery surgical procedure. This data will be used to assess if there are any differences in patient reported pain outcomes between both groups. | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Enrolling by invitation |
NCT05534490 -
Surgery and Functionality in Older Adults
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Terminated |
NCT04612491 -
Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
|
||
Recruiting |
NCT06397287 -
PROM Project Urology
|
||
Recruiting |
NCT04444544 -
Quality of Life and High-Risk Abdominal Cancer Surgery
|
||
Completed |
NCT04204785 -
Noise in the OR at Induction: Patient and Anesthesiologists Perceptions
|
N/A | |
Completed |
NCT03432429 -
Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
|
||
Completed |
NCT04176822 -
Designing Animated Movie for Preoperative Period
|
N/A | |
Recruiting |
NCT05370404 -
Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain:
|
N/A | |
Not yet recruiting |
NCT05467319 -
Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS
|
Phase 3 | |
Recruiting |
NCT04602429 -
Children's Acute Surgical Abdomen Programme
|
||
Completed |
NCT03124901 -
Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor
|
N/A | |
Completed |
NCT04595695 -
The Effect of Clear Masks in Improving Patient Relationships
|
N/A | |
Recruiting |
NCT06103136 -
Maestro 1.0 Post-Market Registry
|
||
Completed |
NCT05346588 -
THRIVE Feasibility Trial
|
Phase 3 | |
Completed |
NCT04059328 -
Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
|
||
Recruiting |
NCT03697278 -
Monitoring Postoperative Patient-controlled Analgesia (PCA)
|
N/A |